<DOC>
	<DOC>NCT01727141</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.</brief_summary>
	<brief_title>A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.</brief_title>
	<detailed_description>NOTE: Detailed Description: data not entered</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male and female patients that have signed informed consent and are &gt;/= 40 years of age. Patients with stable COPD according to GOLD 2011. Patients with a postbronchodilator FEV1 of &gt;/= 30% and &lt; 80% predicted and a postbronchodilator FEV1/FVC &lt;0.70. Current or exsmokers who have a smoking history of at least 10 pack years. Patients with an mMRC grade 2 or greater. Patients with Type I or uncontrolled Type II diabetes Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (&gt;450 ms for males and females) and confirmed by a central assessor. (These patients should not be rescreened.) Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102. (These patients should not be rescreened.) Patients with a history of malignancy of any organ system, treated or untreated, within the last five years. Patients with narrowangle glaucoma, BPH or bladderneck obstruction or moderatesevere renal impairment or urinary retention. Patients who had a COPD exacerbation within 6 weeks prior to screening. Patients who have a respiratory tract infection within 4 weeks prior to screening. Patients requiring long term oxygen therapy prescribed for more than 12 hr per day. Patients with a history of asthma. 8. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to age 40 years. Patients with a blood eosinophil count of greater than 600 mm/3 during runin. Patients with concomitant pulmonary disease. Patients with a diagnosis of alpha1 antitrypsin deficiency. Patients with active pulmonary tuberculosis. Patients in the active phase of a pulmonary rehabilitation programme. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>COPD, QVA149</keyword>
</DOC>